The Company's stock listing will benoted with

Unless a replacement is namedin the interim, the position of CFO will be filled by Mr Chen Si Qiang, CEO andChairman of the Board.Mr Chen stated, "We greatly appreciate Mr. The Company's coreproducts are urea and other coal-based chemicals primarily utilized asfertilizers. Future growth is anticipated from its focus on expanding productionof coal-based alternative fuels, in particular, methanol, as an additive togasoline and dimethyl ether (DME), which has been a cheaper, moreenvironmentally friendly alternative to LPG for home heating and cooking, anddiesel fuel for cars and buses. All of the Company's sales are made through anetwork of distribution partners in the PRC. Additional information on theCompany is available on its website at Harbor StatementThis press release may contain forward-looking statements concerning NewOriental Energy & Chemical Corp.

The actual results may differ materiallydepending on a number of risk factors including, but not limited to, thefollowing: general economic and business conditions, development, shipment,market acceptance, additional competition from existing and new competitors,changes in technology or product techniques, and various other factors beyondits control. All forward-looking statements are expressly qualified in theirentirety by this Cautionary Statement and the risk factors detailed in theCompany's reports filed with the Securities and Exchange Commission NewOriental Energy & Chemical Corp. Ben Wang, Chief Financial Officer(011-86) 10-6709-2670Xicheng Industrial Zone of Luoshan, XinyangHenan Province, The People's Republic of ChinaEast West Network GroupInvestors:Mark Miller (770) DGI Investor RelationsPress:Ken Donenfeld(212) 425-5700Fax: (212) . RESEARCH TRIANGLE PARK, NORTH CAROLINA, Jan 09 (MARKETWIRE) Adherex Technologies Inc. (TSX: AHX) (AMEX: ADH), a biopharmaceuticalcompany dedicated to solving problems for patients with cancer, todayannounced that the Company has filed to voluntarily delist its commonstock from the NYSE Alternext US LLC (formerly, the American StockExchange or "AMEX").

After receiving a notice from AMEX indicating thatthe Company failed to meet certain of the AMEX continued listingrequirements, as previously announced by the Company on December 10,2008, the Company's Board of Directors elected not to submit a plan ofcompliance and voluntarily file for delisting.To effect the delisting, the Company intends to file with the Securitiesand Exchange Commission a Form 25, Notification of Removal from Listingand/or Registration, on or about January 19, 2009. The Company expectsthat trading of its shares on the AMEX will be terminated on or aboutJanuary 29, 2009. Until the AMEX delisting becomes effective on or aboutJanuary 29, 2009, the Company's common stock will continue to trade onthe AMEX under the symbol "ADH". The Company's stock listing will benoted with ".BC" after its trading symbol to reflect its non-compliancewith the AMEX listing requirements. The Company's common stock continuesto trade under the symbol "AHX" on the Toronto Stock Exchange About Adherex TechnologiesAdherex Technologies Inc.

is a biopharmaceutical company dedicated to thediscovery and development of novel cancer therapeutics. We are in thebusiness of solving problems for patients with cancer. We have multipleproducts in the clinical stage of development, including eniluracil,ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidinedehydrogenase (DPD) inhibitor, is being developed to improve thetolerability and effectiveness of 5-fluorouracil (5-FU), one of the mostwidely used oncology drugs in the world. ADH-1 is a biotechnologycompound which selectively targets N-cadherin, a protein present oncertain tumor cells and the blood vessels of solid tumors.